Quoin Pharmaceuticals, Ltd. (QNRX)

NASDAQ: QNRX · IEX Real-Time Price · USD
0.620
-0.044 (-6.70%)
At close: Jul 19, 2024, 4:00 PM
0.623
+0.003 (0.45%)
After-hours: Jul 19, 2024, 4:25 PM EDT
-6.70%
Market Cap 2.35M
Revenue (ttm) n/a
Net Income (ttm) -8.41M
Shares Out 3.80M
EPS (ttm) -6.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 85,530
Open 0.679
Previous Close 0.665
Day's Range 0.574 - 0.680
52-Week Range 0.570 - 12.000
Beta 2.00
Analysts Strong Buy
Price Target 4.00 (+545.16%)
Earnings Date Jul 31, 2024

About QNRX

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consult... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Employees 4
Stock Exchange NASDAQ
Ticker Symbol QNRX
Full Company Profile

Financial Performance

Financial numbers in ILS Financial Statements

Analyst Forecast

According to one analyst, the rating for QNRX stock is "Strong Buy" and the 12-month stock price forecast is $4.0.

Price Target
$4.0
(545.16% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference

ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan disea...

26 days ago - GlobeNewsWire

Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland

Agreement will focus on the development of novel topical rapamycin (sirolimus) formulations as potential treatments for a number of rare and orphan diseases

5 weeks ago - GlobeNewsWire

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into late ...

2 months ago - GlobeNewsWire

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseas...

2 months ago - GlobeNewsWire

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical ...

4 months ago - GlobeNewsWire

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan dise...

4 months ago - GlobeNewsWire

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin P...

Other symbols: SKVI
5 months ago - Accesswire

Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

Positive initial data and clean safety profile catalyze optimization plan Size of both ongoing clinical trials significantly increased Lower dose eliminated from blinded trial Dosing frequency changed...

7 months ago - GlobeNewsWire

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results

Company reported positive clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study

9 months ago - GlobeNewsWire

Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET

ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan disea...

9 months ago - GlobeNewsWire

REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Available Clinical Data from Six Subjects Demonstrates Well Defined Efficacy Signals Across a Number of Study Endpoints

9 months ago - GlobeNewsWire

Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Available Clinical Data from Six Subjects Demonstrates Well Define Efficacy Signals Across a Number of Study Endpoints

9 months ago - GlobeNewsWire

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2023 Financial Results

Company reports positive clinical data for first subject to complete testing in ongoing open-label Netherton Syndrome study

1 year ago - GlobeNewsWire

Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial

ASHBURN, Va., May 24, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan disea...

1 year ago - GlobeNewsWire

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results

First patient dosed in Quoin's single arm, open label clinical trial in Netherton Syndrome patients currently receiving off-label systemic therapy

1 year ago - GlobeNewsWire

Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET

ASHBURN, Va., May 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseas...

1 year ago - GlobeNewsWire

Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial

ASHBURN, Va., March 21, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan dis...

1 year ago - GlobeNewsWire

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results

ASHBURN, Va., March 08, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan dis...

1 year ago - GlobeNewsWire

Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET

ASHBURN, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan dis...

1 year ago - GlobeNewsWire

Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

ASHBURN, Va., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan dise...

1 year ago - GlobeNewsWire

Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome

Company's Second Netherton Syndrome Clinical Study has been Cleared by FDA to Initiate Testing

1 year ago - GlobeNewsWire

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial Results

ASHBURN, Va., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan dise...

1 year ago - GlobeNewsWire

Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th

ASHBURN, Va., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan dise...

1 year ago - GlobeNewsWire

Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients

A Multicenter Open Label Study of QRX003 Topical Lotion in Netherton Syndrome Patients Who Are Currently Receiving Systemic Biologic Therapy. A Multicenter Open Label Study of QRX003 Topical Lotion in...

1 year ago - GlobeNewsWire

Quoin Pharmaceuticals Establishes Patient Specific Website for Ongoing Netherton Syndrome Clinical Study

Three clinical sites are now fully open; final three sites expected to open imminently Three clinical sites are now fully open; final three sites expected to open imminently

2 years ago - GlobeNewsWire